UBS Maintains Neutral on Corteva, Raises Price Target to $90

Benzinga Newsdesk www.benzinga.com Positive 58.8%

Neg 0% Neu 0% Pos 58.8%

UBS analyst Joshua Spector maintains Corteva (NYSE:CTVA) with a Neutral and raises the price target from $88 to $90.

Comments

No comments yet. Be the first!